News & Events
News & Events
Institut Pasteur Korea Discusses AI Drug Discovery Platform Research with K-MELLODDY Project Group
2025-03-26
Institut Pasteur Korea Discusses AI Drug Discovery Platform Research with K-MELLODDY Project Group
On March 4, Institut Pasteur Korea (IPK) held a meeting with the K-MELLODDY (Korea Machine Learning Ledger Orchestration for Drug Discovery) Project Group to review the progress of ongoing projects and discuss overall program operations.
The K-MELLODDY consortium is a national project jointly led by the Ministry of Science and ICT and the Ministry of Health and Welfare, with support from the National Research Foundation of Korea and the Korea Health Industry Development Institute. It aims to establish an AI-based drug discovery platform utilizing federated learning models.
IPK is participating in the project by contributing to the drug discovery data utilization and quality management sector.
To support AI-based drug discovery using small-molecule compounds, IPK collects ADMET data from its internally developed and synthesized compounds through phenomic screening technologies, contributing to the construction of AI prediction models.
The K-MELLODDY consortium is a national project jointly led by the Ministry of Science and ICT and the Ministry of Health and Welfare, with support from the National Research Foundation of Korea and the Korea Health Industry Development Institute. It aims to establish an AI-based drug discovery platform utilizing federated learning models.
IPK is participating in the project by contributing to the drug discovery data utilization and quality management sector.
To support AI-based drug discovery using small-molecule compounds, IPK collects ADMET data from its internally developed and synthesized compounds through phenomic screening technologies, contributing to the construction of AI prediction models.
.png)
The meeting was attended by IPK CEO Sung Key Jang, along with researchers from the AI Drug Discovery Lab, Screening Platform Lab, and Applied Molecular Biochemistry Lab. The K-MELLODDY project group was represented by Project Director Hwa Jong Kim and three additional members.
The session included a review of data preparation status, project operations, and potential areas for collaboration. Participants also toured the research facilities at IPK.
Moving forward, IPK will continue to advance AI-driven drug discovery research and contribute to the development of a robust AI-based drug discovery ecosystem.